{
  "retracted": false,
  "timestamp": 1480550400000,
  "updates": [
    {
      "timestamp": 1495657110814,
      "identifier": {
        "doi": "10.1136/gutjnl-2016-312444corr1"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1136/gutjnl-2016-312444"
  },
  "journal": "Gut",
  "publisher": "BMJ",
  "title": "\n            Erratum:\n            Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort\n          "
}
